Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease

Clinical Neuropharmacology

Volumn 19, Issue 3, 1996, Pages 213-221

  Bordet, R ^a,c   Broly, F ^b   Destee A ^a,e   Libersa, Ch ^c   Lafitte, J J ^d  

^a Hôpital Ste Marguerite   (France)

^b Serv de Biochim et de Biol Molec   (France)

^c Service de Pharmacologie Hospitalière   (France)

^d UNIV LILLE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

CYP2D6 Polymorphism; Debrisoquine metabolism; Idiopathic Parkinson's disease; Pharmacogenetic

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DNA; NEUROTOXIN; SPARTEINE; TETRAHYDROISOQUINOLINE;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLISM; PARKINSON DISEASE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0029876756     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619030-00003     Document Type: Article

References (46)

1. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to MPTP. Neurology 1985;35:969-76.
2. Ohta S, Tachikawa O, Makino Y, Tasaki Y, Hirobe M. Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ), a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci 1990;46:599-605.
3. Barbeau A, Roy M, Cloutier T, Plasse L, Paris S. Environmental and genetic factors in the etiology of Parkinson's disease. Adv Neurol 1987;45:299-306.
4. Golbe LI, Lazzarini AM, Schwarz KO, Mark MH, Dickson DW, Duvoisin RC. Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology. Neurology 1993;43: 2222-7.
5. Waters CH, Miller CA. Autosomal-dominant Lewy body parkinsonism in a four-generation family. Ann Neurol 1994;35:59-64.
6. Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson's disease: a reappraisal. Mov Disord 1990;5:187-94.
7. Shahi GS, Das NP, Moochhala SM. Parkinson's disease and cytochrome P450: a possible link. Med Hypotheses 1990;32:277-82.
8. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez F. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and pseudogene. Am J Hum Genet 1989;45:889-904.
9. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphism hydroxylation of debrisoquine in man. Lancet 1977;ii:584-6.
10. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isoenzymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987;148:1144-50.
11. Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in parkinsonian patients treated with antihistamine drugs. Lancet 1987;ii:386.
12. Comella CL, Tanner CM, Goetz CG, Gans S, Rapp D, Fischer J. Debrisoquine metabolism in Parkinson's disease. Neurology 1987;(suppl 1):261-2.
13. Steventon GB, Heafield MTE, Sturman SG, Warring RH, Williams AC, Ellingham J. Degenerative neurological disease and debrisoquine-4-hydroxylation capacity. Med Sci Res 1989;17:163-4.
14. Gudjonsson O, Sanz E, Alvan G, Aquilonius SM, Reviriego J. Poor hydoxylator phenotypes of debrisoquine are not overrepresented in a group of patients with Parkinson's disease. Br J Clin Pharmacol 1990;30:301-2.
15. Meillard MM, Bentue-Ferrer D, Brunet-Bourgin F, Morel G, Allain H. Etude de l'hydroxylation de la débrisoquine dans la maladie de Parkinson. Presse Med 1990;19:947-9.
16. Benitez J, Ladero JM, Jiminez-Jiminez FJ. Oxidative metabolism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:289-92.
17. Kallio J., Martilli RJ, Rinne UK, Sonninen V, Syvalahti E. Debrisoquin oxidation in Parkinson's disease. Acta Neurol Scand 1991;83:194-7.
18. Steiger MJ, Lledo P, Quinn NP, Marsden CD, Turner P, Jenner PG. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992;86:159-64.
19. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
20. Spurr NK, Gough AC, Smith CAD, Wolf CR. Genetic analysis of cytochrome P450 gene loci. Methods Enzymol 1991;206:149-66.
21. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-58.
22. Smith CA, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-7.
23. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-18.
24. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993;48:166-8.
25. Tsuneoka Y, Matsuo Y, Iwahashi K, Takeuchi H, Ichikawa Y. A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J Biochem 1993;114:263-6.
26. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
27. Duche JC, Joanne C, Barre J, et al. Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Br J Clin Pharmacol 1991;31:533-6.
28. Neitzel HA. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986;73:320-32.
29. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450dbl gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988;85:5240-3.
30. Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Exposure to well water and pesticides in Parkinson's disease: a case-control study in the Madrid area. Mov Disord 1992;7:149-52.
31. Mayeux R, Tang MX, Marder K, Cote LJ, Stern Y. Smoking and Parkinson's disease. Mov Disord 1994;9:207-12.
32. Cholerton S, Arpanahi A, McCracken N, et al. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994;1:62-3.
33. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphism of debrisoquine and mephenytoin in European population. Eur J Clin Pharmacol 1990;39:533-7.
34. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzales FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991;40:63-8.
35. 3H) GBR-12935 binding proteins. Arch Biochem Biophys 1990;276:424-32.
36. Smith MT, Ekström G, Sandy MS, DI Monte D. Molecular mechanisms of MPTP-induced toxicity. VI- Studies on the mechanism of 1-methyl-1,2,3,6-tetrahydropyridines cytotoxicity in isolated hepatocytes. Life Sci 1987;40:741-8.
37. Langston JW, Forno LS, Robert CS, Irwin I. MPTP causes selective damage to the zona compacta of the substantia nigra in the squirrel monkey. Brain Res 1984;292:390-4.
38. + by dopamine neurones explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-7.
39. Masubushi Y, Fujitas S, Chiba M, Kagimoto N, Umeda S, Susuki T. Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol. Biochem Pharmacol 1991;41:861-5.
40. Brosen K, Gram LF, Haghfelt T, Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987;60:312-14.
41. Steventon GB, Heafield MTE, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson's disease. Neurology 1989;39:883-7.
42. Fink JS, Hotamisligil GS, Girmen AS, et al. Allelic variations in the MAO-A gene mark activity state and may predict vulnerability to Parkinson's disease [Abstract]. Neurology 1992;42(suppl 3):173.
43. Kurth JH, Kurth MC, Poduloso SE, Schwanklaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993;33:368-72.
44. Mazetti P, Le Guern E, Bonnet AM, Vidailhet M, Brice A, Agid Y. Familial Parkinson's disease and polymorphism at the CYP2D6 locus. J Neurol Neurosurg Psychiatry 1994;57:871-2.
45. Plante-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:911-13.
46. Gasser T, Wszolek ZK, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994;36:387-96.